Global innovation center will integrate biologics discovery, development and clinical and commercial manufacturing.

Open-access biologics technology platform company WuXi Biologics announced that construction has begun in Fengxian, Shanghai, China on its new global innovation center. The 1.6 million–ft² site will integrate biologics discovery, development and clinical and commercial manufacturing in a modular and flexible design and house more than 3000 scientists.

WuXi Biologics expects the new biologics center to further expand its capacities, enable it to develop and manufacture biologics more cost-effectively and ensure a robust supply chain network for its global partners, according to Chief Executive Officer Dr. Chris Chen.